Accès ouvert
2024
article
OpenAlex
Maurizio Martelli, Luca Ceriani, Giovannino Ciccone, Umberto Ricardi et autres
PURPOSE: The role of consolidation radiotherapy in patients with primary mediastinal B-cell lymphoma (PMBCL) is controversial. METHODS: The IELSG37 trial, a randomized noninferiority study, aimed to assess whether irradiation can be omitted in patients with PMBCL with complete metabolic response (CMR) after …
it, ch, ua, pl, cn, ca, no, cz, gb, se
(code pays fourni par la source)
2024
conference-abstract
OpenAlex
Peter Borchmann, Alden A. Moccia, Richard Greil, Gundolf Schneider et autres
LBA7000 Background: We hypothesized that therapy with the novel BrECADD regimen (brentuximab vedotin, etoposide, cyclophosphamide, doxorubicin, dacarbazine, dexamethasone) guided by positron emission tomography after two cycles (PET2) could improve the treatment of advanced-stage classical Hodgkin lymphoma (AS-cHL). The HD21 trial aimed at …
de, ch, at, au, nl, no
(code pays fourni par la source)
Accès ouvert
2023
article
OpenAlex
Christian Hoffmann, Toke Printz Ringbæk, Anja Eckstein, W. Deya et autres
Irradiation with electrons is the primary treatment regime for localized conjunctival low-grade lymphomas. However, radiation-induced cataracts are a major cause of treatment-related morbidity. This study investigates whether lens-sparing electron irradiation produces sufficient disease control rates while preventing cataract formation. All consecutive patients …
de
(code pays fourni par la source)
2023
conference-abstract
OpenAlex
Peter Borchmann, Alden A. Moccia, Richard Greil, Gundolf Schneider et autres
INTRODUCTION The GHSG-HD21 trial for newly diagnosed adult patients with advanced-stage classical Hodgkin lymphoma (AS-cHL) compares the BrECADD regimen (Brentuximab vedotin, etoposide, cyclophosphamide, doxorubicin, dacarbazine, dexamethasone) to eBEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone) in a PET adapted approach. Separate analyses …
de, ch, at, au, nl, no, dk, se
(code pays fourni par la source)
Accès ouvert
2023
conference-abstract
OpenAlex
Christine Hanoun, Martijn W. Heymans, Sanne Wiegers, Annelies Bes et autres
Background: Accurate detection of patients at high risk of treatment failure following frontline immunochemotherapy in diffuse large B-cell lymphoma (DLBCL) is of paramount importance as these patients might benefit from early treatment escalation. Recently, we introduced the IMPI prognostic model based on …
nl, de, gb, ch, hu
(code pays fourni par la source)
2023
conference-abstract
OpenAlex
Emanuele Zucca, Luca Ceriani, Andrew Davies, Giovannino Ciccone et autres
Background:Primary mediastinal B-cell lymphoma (PMBCL) is clinically and biologically distinct from other types of aggressive lymphoma, it is characterized by a bulky mediastinal mass and most commonly occurs in women between 30 and 40 years of age. Although consolidation radiotherapy (RT) has …
ch, gb, it, ua, br, pl, cn, ca, no, cz, se, de, pt
(code pays fourni par la source)
Accès ouvert
2023
article
OpenAlex
Luca Fischer, Linmiao Jiang, Joerg Thomas Bittenbring, K. Huebel et autres
Mantle cell lymphoma (MCL) is a distinct subtype of B-cell lymphoma and commonly used induction immunochemotherapies include the anti-CD20 antibody rituximab. However, efficacy data for rituximab regarding overall survival (OS) in first line MCL therapy remain conflicting.We report long-term outcomes of a …
de
(code pays fourni par la source)
Accès ouvert
2023
article
OpenAlex
Maurizio Martelli, Luca Ceriani, Emanuele Zucca, Irina Kryachok et autres
Topic: 19. Aggressive Non-Hodgkin lymphoma - Clinical Background: Primary mediastinal B-cell lymphoma (PMBCL) has a good prognosis if remission is rapidly achieved with dose-intensive immunochemotherapy. In these patients, mediastinal radiotherapy (RT) may consolidate responses; however, it increases the risk of second malignancies …
it, ch, ua, pl, cn, ca, no, gb, se, cz, de, pt, us
(code pays fourni par la source)
Accès ouvert
2023
article
OpenAlex
Christian Hoffmann, Christopher Mohr, Patricia Johansson, Anja Eckstein et autres
We systematically analyzed the kinetics of tumor regression, the impact of residual lesions on disease control and the applicability of the Lugano classification in follow-up MRI of orbital non-Hodgkin lymphomas that were irradiated with photons. We retrospectively analyzed a total of 154 …
de
(code pays fourni par la source)
Accès ouvert
2022
article
OpenAlex
Christian Hoffmann, Philipp Rating, Nikolaos E. Bechrakis, Anja Eckstein et autres
We assessed the long-term outcomes and treatment-related adverse effects of patients with Stage I, "orbital-type" lymphomas that were uniformly treated with photons. All consecutive patients diagnosed with low-grade, Ann Arbor Stage IEA orbital lymphoma treated between 1999 and 2020 at our department …
de
(code pays fourni par la source)
Accès ouvert
2022
article
OpenAlex
A. S. Jacob, Sarah Gillessen, Stefanie Kreissl, Annette Pluetschow et autres
PURPOSE: Evidence on the effect of self-protection via social distancing and wearing face-masks on infections during chemotherapy is currently not available. We asked if the occurrence of acute infections during chemotherapy for advanced-stage Hodgkin lymphoma (HL) decreased when COVID-19 protection measures were …
de
(code pays fourni par la source)
Accès ouvert
2021
article
OpenAlex
Nora Liebers, Johannes Duell, Donnacha Fitzgerald, Andrea Kerkhoff et autres
The antibody-drug conjugate polatuzumab vedotin (pola) has recently been approved in combination with bendamustine and rituximab (pola-BR) for patients with refractory or relapsed (r/r) large B-cell lymphoma (LBCL). To investigate the efficacy of pola-BR in a real-world setting, we retrospectively analyzed 105 …
de
(code pays fourni par la source)